x
Filter:
Filters applied
- Regular Research Articles
- lipid metabolismRemove lipid metabolism filter
- AMPKRemove AMPK filter
- Journal of Lipid ResearchRemove Journal of Lipid Research filter
Publication Date
Please choose a date range between 2021 and 2021.
Keyword
- ACADL1
- ACC1
- Acetyl CoA carboxylase1
- Acyl-CoA dehydrogenase and long chain1
- AdipoR1/21
- AMP-Activated protein kinase1
- AMP-activated protein kinase1
- BAT1
- BSA1
- Carnitine palmitoyl transferase1
- CHOL1
- Cholesterol1
- Chylomicron1
- Chylomicron retention disease1
- CM1
- Coat protein complex II1
- COPII1
- CPT11
- CRD1
- CRISPR/Cas91
- HFD1
- INS-1 beta cells1
- ITT1
Regular Research Articles
2 Results
- Research ArticleOpen Access
Sar1b mutant mice recapitulate gastrointestinal abnormalities associated with chylomicron retention disease
Journal of Lipid ResearchVol. 62100085Published online: May 5, 2021- Nickolas Auclair
- Alain T. Sané
- Lena Ahmarani
- Nathalie Patey
- Jean-François Beaulieu
- Noel Peretti
- and others
Cited in Scopus: 0Chylomicron retention disease (CRD) is an autosomal recessive disorder associated with biallelic Sar1b mutations leading to defects in intracellular chylomicron (CM) trafficking and secretion. To date, a direct cause-effect relationship between CRD and Sar1b mutation has not been established, but genetically modified animal models provide an opportunity to elucidate unrecognized aspects of these mutations. To examine the physiological role and molecular mechanisms of Sar1b function, we generated mice expressing either a targeted deletion or mutation of human Sar1b using the CRISPR-Cas9 system. - Research ArticleOpen Access
PEGylated AdipoRon derivatives improve glucose and lipid metabolism under insulinopenic and high-fat diet conditions
Journal of Lipid ResearchVol. 62100095Published online: June 29, 2021- Toshiharu Onodera
- Ebrahim Ghazvini Zadeh
- Peng Xu
- Ruth Gordillo
- Zheng Guo
- Nolwenn Joffin
- and others
Cited in Scopus: 0The pleiotropic actions of adiponectin in improving cell survival and metabolism have motivated the development of small-molecule therapeutic agents for treating diabetes and lipotoxicity. AdipoRon is a synthetic agonist of the adiponectin receptors, yet is limited by its poor solubility and bioavailability. In this work, we expand on the protective effects of AdipoRon in pancreatic β-cells and examine how structural modifications could affect the activity, pharmacokinetics, and bioavailability of this small molecule.